A science advisory from the American Heart Association recommended that prescription n-3 fatty acids (eicosapentaenoic acid [EPA]+docosahexaenoic acid [DHA] or EPA-only) at a dose of 4 g/d (>3 g/d total EPA+DHA) are an effective and safe option for reducing triglycerides as monotherapy or as an adjunct to other lipid-lowering agents (https://www.ahajournals.org/). AstraZeneca announced that compared to placebo, dapagliflozin (a SGLT2 inhibitor) significantly reduced cardiovascular death or the worsening of heart failure (HF, defined as hospitalization or an urgent HF visit) in patients with and without type 2 diabetes with reduced ejection fraction on standard of care treatment (https://www.astrazeneca-us.com/). Data from a US community‐based cohort of 12 168 middle‐aged adults suggest that diets higher in plant foods and lower in animal foods were associated with a lower risk of cardiovascular morbidity and mortality in a general population (https://www.ahajournals.org/).
Both clinician-rated and patient-reported outcomes suggested that mindfulness-based stress reduction (MBSR) was well-tolerated with comparable…
The number of individuals with high blood pressure (BP) is increasing worldwide. The trajectory of…
A single combined measure of high-sensitivity C-reactive protein (CRP), low-density lipoprotein (LDL) cholesterol, and lipoprotein(a)…
A French multicenter, open label, randomized, noninferiority trial suggested that interruption of long-term beta-blocker treatment…
A US prospective cohort study demonstrated that replacement of animal fat with an equivalent amount…
An ongoing UK national prospective program shows remission of type 2 diabetes (T2D) outside of…
This website uses cookies.